文献速递药物相互作用

预测转运体介导的药物相互作用:两篇鸡尾酒试验研究的评论

Predicting transporter-mediated drug interactions: Commentary on: "Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin" and "Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A".
PubMed 文献 · Clin Pharmacol Ther · 2017-02-18

本文评论两项关于转运体介导药物相互作用评估的鸡尾酒试验研究,讨论转运体在药物处置中的作用及转运体介导DDI在药物开发和监管审评中的风险评估意义。

要点

  • 转运体影响药物吸收、分布、代谢和排泄,进而影响安全性和有效性。
  • 药物可作为转运体底物和/或抑制剂,理解转运体介导DDI是风险评估的组成部分。
  • 患者常同时使用多种药物,转运体介导DDI评估在药物开发和监管审评中不可或缺。

核心结论

  • 理解转运体介导的药物相互作用,与酶介导的DDI一样,是药物开发和监管审评中风险评估的组成部分。

主要发现

  • 转运体在多种组织中表达,调控药物的吸收、分布、代谢和排泄,从而影响药物固有的安全性和有效性。
  • 药物可作为转运体的底物和/或抑制剂,参与转运体介导的相互作用。

临床怎么用

  • 在药物开发和临床用药风险评估中,除酶介导DDI外,也应关注转运体介导DDI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transporters, expressed in various tissues, govern the absorption, distribution, metabolism, and excretion of drugs, and consequently their inherent safety and efficacy profiles. Drugs may interact with a transporter as a substrate and/or an inhibitor. Understanding transporter-mediated drug-drug interactions (DDIs), in addition to enzyme-mediated DDIs, is an integral part of risk assessment in drug development and regulatory review because the concomitant use of more than one medication in patients is common.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Zhang L, Sparreboom A. Predicting transporter-mediated drug interactions: Commentary on: "Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin" and "Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A". Clin Pharmacol Ther. 2017. PMID: 27981558. doi:10.1002/cpt.588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。